Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Clin Oncol ; 20(8): 2053-7, 2002 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-11956265

RESUMEN

PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFN alpha)-2b. PATIENTS AND METHODS: E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months' follow-up and studied using Cox regression analysis. RESULTS: Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P =.0008) and OS (P =.05). ECS correlated with RFS (hazard ratio = 1.44, P =.032) but not OS (P =.11). CONCLUSION: The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P =.0008) and OS (P =.053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS.


Asunto(s)
Antineoplásicos/uso terapéutico , Interferón-alfa/uso terapéutico , Melanoma/tratamiento farmacológico , Melanoma/patología , Humanos , Interferón alfa-2 , Metástasis Linfática , Índice Mitótico , Estadificación de Neoplasias , Proteínas Recombinantes , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Análisis de Supervivencia , Úlcera
2.
Cancer Genet Cytogenet ; 140(1): 37-44, 2003 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-12550756

RESUMEN

Microdissection genotyping was performed on 16 cases of melanoma, including two cutaneous and one lymph node metastases. Three benign nevi were used as controls. Where possible, tumor was microdissected at several sites. Genotyping involved assessment of loss of heterozygosity [LOH]), which was accomplished using a panel of nine polymorphic tetranucleotide microsatellites. Polymerase chain reaction was performed on the normal tissue sample to establish microsatellite heterozygous status. Informative markers were then tested on microdissected lesional tissue and scored for the presence and extent of allelic imbalance (AI). Microsatellite informativeness varied from 33% to 66%. Benign nevi were without AI. All invasive melanomas manifested acquired allelic loss, which involved 75% or 100% of the markers shown to be informative for each subject. Eleven of 13 (84%) primary melanomas demonstrated intratumoral heterogeneity of AI consistent with development of tumor subclones with differing genotypic profiles within thin as well as thick melanomas. Although a consistent pattern did not emerge among the markers, LOH of 9p21 (D9S254) occurred in 60% (9/15) of the cases followed by 40% of cases displaying LOH of 1p34, p53, 10q (MXI1), and 10q23 (D10S520) and 25% with 5q21 (D5S 592) abnormalities. A third of the cases including the metastatic foci demonstrated two different patterns of AI affecting alternative alleles of the same genomic marker within different parts of the melanoma. Two melanomas in situ did not display LOH of any markers in the informative cases although the in situ component in the invasive tumors had allelic losses that were in part similar to the invasive areas. The results of this study support the expanded use of microdissection genotyping and explore other markers to define the unique mutational profile for malignant melanoma that may complement other histologic characteristics of melanoma.


Asunto(s)
Aberraciones Cromosómicas , Melanoma/genética , Neoplasias Cutáneas/genética , Alelos , Cromosomas Humanos/genética , Cromosomas Humanos/ultraestructura , Células Clonales/ultraestructura , Análisis Mutacional de ADN , ADN de Neoplasias/genética , Femenino , Eliminación de Gen , Heterogeneidad Genética , Genotipo , Humanos , Pérdida de Heterocigocidad , Metástasis Linfática , Masculino , Melanoma/patología , Melanoma/secundario , Repeticiones de Microsatélite , Invasividad Neoplásica , Nevo Pigmentado/genética , Nevo Pigmentado/patología , Neoplasias Cutáneas/patología , Neoplasias de la Vulva/genética , Neoplasias de la Vulva/patología
3.
Histopathology ; 51(4): 499-508, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17711449

RESUMEN

AIMS: Leiomyosarcomas (LMS) are malignant neoplasms composed of cells that exhibit distinct smooth muscle differentiation. The molecular and cytogenetic features of LMS are complex and no consistent aberrations have been reported to date. Mitogen inducible gene-2 (Mig-2), kindlin and migfilin are recently identified cell-matrix adhesion proteins. The aim was to determine the expression and distribution of these proteins in human smooth muscle tumours of somatic soft tissue. METHODS AND RESULTS: Immunohistochemistry was performed on a human LMS tissue microarray and on sections of human leiomyomas (LM) and normal smooth muscle. Migfilin was barely detectable in normal smooth muscle cells, whereas increased levels of migfilin were observed in the majority of LM and LMS. Furthermore, the cytoplasmic level of migfilin was strongly associated with higher tumour grades. Additionally, the cytoplasmic levels of migfilin and Mig-2 were correlated with each other, suggesting an association between the two in the cytoplasm. Kindlin was expressed in normal smooth muscle, LM and LMS, and its level did not correlate with tumour grade. CONCLUSIONS: Our results suggest a role for cytoplasmic migfilin in the progression of LMS and identify cytoplasmic migfilin as a potentially important biological marker for human LMS progression.


Asunto(s)
Moléculas de Adhesión Celular/metabolismo , Citoplasma/metabolismo , Proteínas del Citoesqueleto/metabolismo , Leiomiosarcoma/metabolismo , Neoplasias de los Tejidos Blandos/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores de Tumor/metabolismo , Biopsia , Citoplasma/patología , Femenino , Humanos , Leiomiosarcoma/patología , Masculino , Proteínas de la Membrana/metabolismo , Análisis por Micromatrices , Persona de Mediana Edad , Músculo Liso/metabolismo , Músculo Liso/patología , Proteínas de Neoplasias/metabolismo , Neoplasias de los Tejidos Blandos/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA